{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T19:08:00Z","timestamp":1790622480951,"version":"4.1.0"},"reference-count":42,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2014,5,2]],"date-time":"2014-05-02T00:00:00Z","timestamp":1398988800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0095847","type":"journal-article","created":{"date-parts":[[2014,5,2]],"date-time":"2014-05-02T16:26:44Z","timestamp":1399048004000},"page":"e95847","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":11,"title":["Routes of Delivery for CpG and Anti-CD137 for the Treatment of Orthotopic Kidney Tumors in Mice"],"prefix":"10.1371","volume":"9","author":[{"given":"Jennifer A.","family":"Westwood","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Titaina C. U.","family":"Potdevin Hunnam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hollie J.","family":"Pegram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodney J.","family":"Hicks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip K.","family":"Darcy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael H.","family":"Kershaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2014,5,2]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.uct.2007.11.003","article-title":"CpG oligodeoxynucleotides as immunotherapy in cancer","volume":"3","author":"B Jahrsdorfer","year":"2008","journal-title":"Update Cancer Ther"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"4119","DOI":"10.3748\/wjg.v19.i26.4119","article-title":"Epithelial Toll-like receptor 9 signaling in colorectal inflammation and cancer: clinico-pathogenic aspects","volume":"19","author":"I Furi","year":"2013","journal-title":"World J Gastroenterol"},{"key":"ref3","first-page":"47","article-title":"Immunotherapy of melanoma with the immune costimulatory monoclonal antibodies targeting CD137","volume":"5","author":"SY Li","year":"2013","journal-title":"Clin Pharmacol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1158\/1535-7163.MCT-11-0677","article-title":"Immunotherapy of cancer with 4-1BB","volume":"11","author":"DS Vinay","year":"2012","journal-title":"Mol Cancer Ther"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"7624","DOI":"10.1158\/1078-0432.CCR-09-2201","article-title":"Toll-Like Receptor Triggering and T-Cell Costimulation Induce Potent Antitumor Immunity in Mice","volume":"15","author":"JA Westwood","year":"2009","journal-title":"Clin Cancer Res"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1023\/A:1006140513233","article-title":"Orthotopic models are necessary to predict therapy of transplantable tumors in mice","volume":"17","author":"JJ Killion","year":"1998","journal-title":"Cancer Metastasis Rev"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.ejca.2003.11.021","article-title":"Orthotopic models of cancer for preclinical drug evaluation: advantages and disadvantages","volume":"40","author":"MC Bibby","year":"2004","journal-title":"Eur J Cancer"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"793","DOI":"10.2353\/ajpath.2007.060929","article-title":"Murine models to evaluate novel and conventional therapeutic strategies for cancer","volume":"170","author":"JE Talmadge","year":"2007","journal-title":"Am J Pathol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/nrc3001","article-title":"Mouse models of advanced spontaneous metastasis for experimental therapeutics","volume":"11","author":"G Francia","year":"2011","journal-title":"Nat Rev Cancer"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1093\/annonc\/mdr362","article-title":"Distribution of metastatic sites in renal cell carcinoma: a population-based analysis","volume":"23","author":"M Bianchi","year":"2012","journal-title":"Ann Oncol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/1479-5876-8-42","article-title":"Three agonist antibodies in combination with high-dose IL-2 eradicate orthotopic kidney cancer in mice","volume":"8","author":"JA Westwood","year":"2010","journal-title":"J Transl Med"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"e59536","DOI":"10.1371\/journal.pone.0059536","article-title":"Ultrasound-guided intramural inoculation of orthotopic bladder cancer xenografts: a novel high-precision approach","volume":"8","author":"W Jager","year":"2013","journal-title":"PLoS One"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s11523-013-0273-x","article-title":"Ultrasound-guided direct delivery of 3-bromopyruvate blocks tumor progression in an orthotopic mouse model of human pancreatic cancer","volume":"8","author":"S Ota","year":"2013","journal-title":"Target Oncol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"701","DOI":"10.3748\/wjg.v9.i4.701","article-title":"Experimental study on ultrasound-guided intratumoral injection of \u201cStar-99\u201d in treatment of hepatocellular carcinoma of nude mice","volume":"9","author":"LW Lin","year":"2003","journal-title":"World J Gastroenterol"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1093\/jnci\/50.4.1013","article-title":"A murine renal cell carcinoma","volume":"50","author":"GP Murphy","year":"1973","journal-title":"J Natl Cancer Inst"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1172\/JCI31414","article-title":"Development of TLR9 agonists for cancer therapy","volume":"117","author":"AM Krieg","year":"2007","journal-title":"J Clin Invest"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/j.jaad.2009.12.052","article-title":"Phase I trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-cell lymphoma","volume":"63","author":"YH Kim","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"211","DOI":"10.3109\/10428194.2011.608451","article-title":"Phase I clinical trial of CpG oligonucleotide 7909 (PF-03512676) in patients with previously treated chronic lymphocytic leukemia","volume":"53","author":"CS Zent","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3389\/fonc.2012.00101","article-title":"CpG plus radiotherapy: a review of preclinical works leading to clinical trial","volume":"2","author":"KA Mason","year":"2012","journal-title":"Front Oncol"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1038\/bjc.2013.227","article-title":"Phase I study of tremelimumab (CP-675 206) plus PF-3512676 (CPG 7909) in patients with melanoma or advanced solid tumours","volume":"108","author":"M Millward","year":"2013","journal-title":"Br J Cancer"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s00262-011-0984-8","article-title":"Adoptive immunotherapy combined with intratumoral TLR agonist delivery eradicates established melanoma in mice","volume":"60","author":"SM Amos","year":"2011","journal-title":"Cancer Immunol Immunother"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/nm1405","article-title":"Eradication of established tumors in mice by a combination antibody-based therapy","volume":"12","author":"T Uno","year":"2006","journal-title":"Nat Med"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1158\/0008-5472.CAN-09-1574","article-title":"Multiple antitumor mechanisms downstream of prophylactic regulatory T-cell depletion","volume":"70","author":"MW Teng","year":"2010","journal-title":"Cancer Res"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1007\/s00262-011-1075-6","article-title":"Signals through 4-1BB inhibit T regulatory cells by blocking IL-9 production enhancing antitumor responses","volume":"60","author":"SE Smith","year":"2011","journal-title":"Cancer Immunol Immunother"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.canlet.2012.11.045","article-title":"Combined stimulation of TLR9 and 4.1BB augments Trp2 peptide vaccine-mediated melanoma rejection by increasing Ag-specific CTL activity and infiltration into tumor sites","volume":"330","author":"JI Sin","year":"2013","journal-title":"Cancer Lett"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/ijc.2910520118","article-title":"Orthotopic and ectopic organ environments differentially influence the sensitivity of murine colon carcinoma cells to doxorubicin and 5-fluorouracil","volume":"52","author":"C Wilmanns","year":"1992","journal-title":"Int J Cancer"},{"key":"ref27","first-page":"413","article-title":"Modulation of Doxorubicin sensitivity and level of p-glycoprotein expression in human colon-carcinoma cells by ectopic and orthotopic environments in nude-mice","volume":"3","author":"C Wilmanns","year":"1993","journal-title":"Int J Oncol"},{"key":"ref28","first-page":"627","article-title":"Site-specific chemosensitivity of human small-cell lung carcinoma growing orthotopically compared to subcutaneously in SCID mice: the importance of orthotopic models to obtain relevant drug evaluation data","volume":"13","author":"TH Kuo","year":"1993","journal-title":"Anticancer Res"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"4843","DOI":"10.1158\/1078-0432.CCR-10-1206","article-title":"Hypoxia in models of lung cancer: implications for targeted therapeutics","volume":"16","author":"EE Graves","year":"2010","journal-title":"Clin Cancer Res"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1136\/gutjnl-2011-301585","article-title":"Metronomic oral topotecan prolongs survival and reduces liver metastasis in improved preclinical orthotopic and adjuvant therapy colon cancer models","volume":"62","author":"C Hackl","year":"2013","journal-title":"Gut"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/mt.2013.219","article-title":"Tissues in different anatomical sites can sculpt and vary the tumor microenvironment to affect responses to therapy","volume":"22","author":"C Devaud","year":"2014","journal-title":"Mol Ther"},{"key":"ref32","unstructured":"Ruggeri BA, Camp F, Miknyoczki S (2013) Animal models of disease: Pre-clinical animal models of cancer and their applications and utility in drug discovery. Biochem Pharmacol S0006-2952(13)00391-2. doi:<ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/dx.doi.org\/10.1016\/j.bcp.2013.06.020\" xlink:type=\"simple\">10.1016\/j.bcp.2013.06.020<\/ext-link>. [Epub ahead of print]."},{"key":"ref33","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nrd3870","article-title":"The role of tumour-stromal interactions in modifying drug response: challenges and opportunities","volume":"12","author":"DW McMillin","year":"2013","journal-title":"Nat Rev Drug Discov"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.bcp.2013.06.020","article-title":"Animal models of disease: Pre-clinical animal models of cancer and their applications and utility in drug discovery","volume":"87","author":"BA Ruggeri","year":"2014","journal-title":"Biochem Pharmacol"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1186\/1748-717X-7-223","article-title":"Preclinical models in radiation oncology","volume":"7","author":"J Kahn","year":"2012","journal-title":"Radiat Oncol"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"e31085","DOI":"10.1371\/journal.pone.0031085","article-title":"Eradication of metastatic renal cell carcinoma after adenovirus-encoded TNF-related apoptosis-inducing ligand (TRAIL)\/CpG immunotherapy","volume":"7","author":"LA Norian","year":"2012","journal-title":"PLoS One"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/sj.cgt.7700519","article-title":"The combination of HSV-tk and endostatin gene therapy eradicates orthotopic human renal cell carcinomas in nude mice","volume":"9","author":"KJ Pulkkanen","year":"2002","journal-title":"Cancer Gene Ther"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"e52178","DOI":"10.1371\/journal.pone.0052178","article-title":"Intratumoral administration of holmium-166 acetylacetonate microspheres: antitumor efficacy and feasibility of multimodality imaging in renal cancer","volume":"8","author":"W Bult","year":"2013","journal-title":"PLoS One"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1158\/1078-0432.CCR-06-2398","article-title":"Combination therapy of an orthotopic renal cell carcinoma model using intratumoral vector-mediated costimulation and systemic interleukin-2","volume":"13","author":"C Kudo-Saito","year":"2007","journal-title":"Clin Cancer Res"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/CJI.0b013e31820d2a05","article-title":"Antitumor activity mediated by CpG: the route of administration is critical","volume":"34","author":"Y Lou","year":"2011","journal-title":"J Immunother"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"e8368","DOI":"10.1371\/journal.pone.0008368","article-title":"Route of administration of the TLR9 agonist CpG critically determines the efficacy of cancer immunotherapy in mice","volume":"4","author":"S Nierkens","year":"2009","journal-title":"PLoS One"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1002\/eji.200526124","article-title":"Improving the therapeutic index of CpG oligodeoxynucleotides by intralymphatic administration","volume":"35","author":"BR von Beust","year":"2005","journal-title":"Eur J Immunol"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0095847","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T18:56:36Z","timestamp":1588964196000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0095847"}},"subtitle":[],"editor":[{"given":"Fabrizio","family":"Mattei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2014,5,2]]},"references-count":42,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2014,5,2]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0095847","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,5,2]]}}}